RHT Fundamental Analysis - RELIQ HEALTH TECHNOLOGIES IN

Name: RELIQ HEALTH TECHNOLOGIES IN (RHT) Stock
Brand: RELIQ HEALTH TECHNOLOGIES IN
Rating: 4 (3 reviews)

Fundamental Rating

We assign a fundamental rating of 4 out of 10 to RHT. RHT was compared to 8 industry peers in the Health Care Technology industry. RHT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RHT is not overvalued while it is showing excellent growth. This is an interesting combination.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year RHT has reported negative net income.

RHT had a negative operating cash flow in the past year.

In the past 5 years RHT always reported negative net income.

RHT had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

RHT has a Return On Assets of -2.05%. This is in the better half of the industry: RHT outperforms 75.00% of its industry peers.

RHT has a Return On Equity of -3.41%. This is amongst the best in the industry. RHT outperforms 87.50% of its industry peers.

		Industry Rank	Sector Rank
ROA	-2.05%
ROE	-3.41%
ROIC	N/A

ROA(3y)-277.14%

ROA(5y)-257.7%

ROE(3y)-803.99%

ROE(5y)-598.14%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of RHT (60.61%) is comparable to the rest of the industry.

In the last couple of years the Gross Margin of RHT has grown nicely.

The Profit Margin and Operating Margin are not available for RHT so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	60.61%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y143.2%

GM growth 5Y26.85%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

RHT does not have a ROIC to compare to the WACC, probably because it is not profitable.

RHT has more shares outstanding than it did 1 year ago.

The debt/assets ratio for RHT has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of 0.13, we must say that RHT is in the distress zone and has some risk of bankruptcy.

RHT has a better Altman-Z score (0.13) than 62.50% of its industry peers.

A Debt/Equity ratio of 0.01 indicates that RHT is not too dependend on debt financing.

The Debt to Equity ratio of RHT (0.01) is better than 87.50% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Altman-Z	0.13

ROIC/WACCN/A

WACC9.53%

2.3 Liquidity

A Current Ratio of 1.86 indicates that RHT should not have too much problems paying its short term obligations.

RHT's Current ratio of 1.86 is amongst the best of the industry. RHT outperforms 100.00% of its industry peers.

A Quick Ratio of 1.79 indicates that RHT should not have too much problems paying its short term obligations.

With an excellent Quick ratio value of 1.79, RHT belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	1.86
Quick Ratio	1.79

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

RHT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 94.41%, which is quite impressive.

Looking at the last year, RHT shows a very strong growth in Revenue. The Revenue has grown by 119.37%.

RHT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 115.82% yearly.

EPS 1Y (TTM)94.41%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%186.44%

Revenue 1Y (TTM)119.37%

Revenue growth 3Y260.91%

Revenue growth 5Y115.82%

Sales Q2Q%88.51%

3.2 Future

RHT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 68.33% yearly.

RHT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 126.89% yearly.

EPS Next Y123.08%

EPS Next 2Y64.08%

EPS Next 3Y68.33%

EPS Next 5YN/A

Revenue Next Year106.52%

Revenue Next 2Y102.94%

Revenue Next 3Y126.89%

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

RHT is valuated cheaply with a Price/Forward Earnings ratio of 6.96.

Based on the Price/Forward Earnings ratio, RHT is valued cheaper than 100.00% of the companies in the same industry.

RHT's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 34.08.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	6.96

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

RHT's earnings are expected to grow with 68.33% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y64.08%

EPS Next 3Y68.33%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for RHT!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

RELIQ HEALTH TECHNOLOGIES IN

TSX-V:RHT (1/16/2024, 7:00:00 PM)

0.215

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Technology

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst Owners0.27%

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap41.56M

Revenue(TTM)14.62M

Net Income(TTM)-457.61K

Analysts84.44

Price Target1.79 (732.56%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	6.96
P/S	2.84
P/FCF	N/A
P/OCF	N/A
P/B	3.1
P/tB	3.1
EV/EBITDA	N/A

EPS(TTM)0

EYN/A

EPS(NY)0.03

Fwd EY14.37%

FCF(TTM)-0.04

FCFYN/A

OCF(TTM)-0.04

OCFYN/A

SpS0.08

BVpS0.07

TBVpS0.07

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-2.05%
ROE	-3.41%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	60.61%
FCFM	N/A

ROA(3y)-277.14%

ROA(5y)-257.7%

ROE(3y)-803.99%

ROE(5y)-598.14%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y143.2%

GM growth 5Y26.85%

F-Score2

Asset Turnover0.66

Health

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.86
Quick Ratio	1.79
Altman-Z	0.13

F-Score2

WACC9.53%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)94.41%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%186.44%

EPS Next Y123.08%

EPS Next 2Y64.08%

EPS Next 3Y68.33%

EPS Next 5YN/A

Revenue 1Y (TTM)119.37%

Revenue growth 3Y260.91%

Revenue growth 5Y115.82%

Sales Q2Q%88.51%

Revenue Next Year106.52%

Revenue Next 2Y102.94%

Revenue Next 3Y126.89%

Revenue Next 5YN/A

EBIT growth 1Y84.21%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year105.4%

EBIT Next 3Y80.52%

EBIT Next 5YN/A

FCF growth 1Y-8.15%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-9.01%

OCF growth 3YN/A

OCF growth 5YN/A

RELIQ HEALTH TECHNOLOGIES IN / RHT.CA FAQ

Can you provide the ChartMill fundamental rating for RELIQ HEALTH TECHNOLOGIES IN?

ChartMill assigns a fundamental rating of 4 / 10 to RHT.CA.

What is the valuation status of RELIQ HEALTH TECHNOLOGIES IN (RHT.CA) stock?

ChartMill assigns a valuation rating of 4 / 10 to RELIQ HEALTH TECHNOLOGIES IN (RHT.CA). This can be considered as Fairly Valued.

How profitable is RELIQ HEALTH TECHNOLOGIES IN (RHT.CA) stock?

RELIQ HEALTH TECHNOLOGIES IN (RHT.CA) has a profitability rating of 2 / 10.

What is the earnings growth outlook for RELIQ HEALTH TECHNOLOGIES IN?

The Earnings per Share (EPS) of RELIQ HEALTH TECHNOLOGIES IN (RHT.CA) is expected to grow by 123.08% in the next year.

RELIQ HEALTH TECHNOLOGIES IN (RHT.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

RELIQ HEALTH TECHNOLOGIES IN / RHT.CA FAQ

Can you provide the ChartMill fundamental rating for RELIQ HEALTH TECHNOLOGIES IN?

What is the valuation status of RELIQ HEALTH TECHNOLOGIES IN (RHT.CA) stock?

How profitable is RELIQ HEALTH TECHNOLOGIES IN (RHT.CA) stock?

What is the earnings growth outlook for RELIQ HEALTH TECHNOLOGIES IN?